Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD.

Publication Type:

Journal Article

Source:

Bone marrow transplantation, Volume 49, Issue 9, p.1198-204 (2014)

Keywords:

2014, August 2014, Center-Authored Paper, Clinical Research Division, Comparative Medicine Core Facility, Experimental Histopathology Core Facility, Flow Cytometry Core Facility, Genomics Core Facility, Research Trials Office Core Facility - Biostatistics Service, Shared Resources

Abstract:

Extracorporeal photopheresis (ECP) and the purine analog pentostatin exert potent immunomodulatory effects. We evaluated the use of these treatment modalities to prevent GVHD in a canine model of unrelated dog leukocyte Ag-mismatched hematopoietic cell transplantation, after conditioning with 920 cGy TBI. We have shown previously in this model that 36/40 dogs given MTX alone as postgrafting immunosuppression engrafted and that 25 of 40 dogs had severe GVHD and median survival of 21 days. In the current study, nine dogs received conditioning with 920 cGy TBI and postgrafting MTX either with ECP on days -2 to -1 alone (n=5) or ECP on days -6 and -5 combined with two doses of pentostatin (days -4 to -3) (n=4). Seven of nine dogs achieved engraftment. Six dogs developed severe acute GVHD (four in the group with ECP alone and two with pentostatin and ECP). We failed to demonstrate a positive impact of ECP and pentostatin for the prevention of GVHD compared with historical control dogs.Bone Marrow Transplantation advance online publication, 21 July 2014; doi:10.1038/bmt.2014.137.